Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 203

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period

Hall, Richard, Mazer, C. David·2011·Anesthesia & Analgesia

Abstract

In the normal course of the delivery of care, anesthesiologists encounter many patients who are receiving drugs that affect platelet function as a fundamental part of primary and secondary management of atherosclerotic thrombotic disease. There are several antiplatelet drugs available for use in clinical practice and several under investigation. Aspirin and clopidogrel (alone and in combination) have been the most studied and have the most favorable risk-benefit profiles of drugs currently available. Prasugrel was recently approved for patients with acute coronary syndrome undergoing percutaneous interventions. Other drugs such as dipyridamole and cilostazol have not been as extensively investigated. There are several newer investigational drugs such as cangrelor and ticagrelor, but whether they confer significant additional benefits remains to be established. Management of patients who are receiving antiplatelet drugs during the perioperative period requires an understanding of the underlying pathology and rationale for their administration, pharmacology and pharmacokinetics, and drug interactions. Furthermore, the risk and benefit assessment of discontinuing or continuing these drugs should be made bearing in mind the proposed surgery and its inherent risk for bleeding complications as well as decisions relating to appropriate use of general or some form of regional anesthesia. In general, the safest approach to prevent thrombosis seems to be continuation of these drugs throughout the perioperative period except where concerns about perioperative bleeding outweigh those associated with the development of thrombotic occlusion. Knowledge of the pharmacodynamics and pharmacokinetics of antiplatelet drugs may allow practitioners to anticipate difficulties associated with drug withdrawal and administration in the perioperative period including the potential for drug interactions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1213/ane.0b013e318203f38d

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 283

  1. Jennings, 2009, Role of platelets in atherothrombosis., Am J Cardiol, 103, 4A, 10.1016/j.amjcard.2008.11.017 · DOI · Paper page
  2. Bhatt, 2009, Role of antiplatelet therapy across the spectrum of patients with coronary artery disease., Am J Cardiol, 103, 11A, 10.1016/j.amjcard.2008.11.018 · DOI
  3. Hirsh, 2008, Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 71S, 10.1378/chest.08-0693 · DOI · Paper page
  4. Albers, 2008, Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 630S, 10.1378/chest.08-0720 · DOI · Paper page
  5. Hankey, 2000, Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients., Cochrane Database Syst Rev, 2, CD001246
  6. Leonardi-Bee, 2005, Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials., Stroke, 36, 162, 10.1161/01.STR.0000149621.95215.ea · DOI
  7. 2002, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients., BMJ, 324, 71, 10.1136/bmj.324.7329.71 · DOI · Paper page
  8. Goodman, 2008, Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 708S, 10.1378/chest.08-0665 · DOI
  9. Harrington, 2008, Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 670S, 10.1378/chest.08-0691 · DOI
  10. Grines, 2007, Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians., Catheter Cardiovasc Interv, 69, 334, 10.1002/ccd.21124 · doi:10.1002/ccd.21124
  11. Helton, 2007, Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials., Am J Cardiovasc Drugs, 7, 289, 10.2165/00129784-200707040-00006 · DOI
  12. Sun, 2008, The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies., Eur Heart J, 29, 1057, 10.1093/eurheartj/ehn104 · DOI
  13. Purkayastha, 2006, Does clopidogrel affect outcome after coronary artery bypass grafting A meta-analysis., Heart, 92, 531, 10.1136/hrt.2004.058396 · DOI
  14. Zimmermann, 2008, Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent., Eur J Cardiothorac Surg, 34, 93, 10.1016/j.ejcts.2008.03.023 · DOI
  15. Eidelman, 2003, An update on aspirin in the primary prevention of cardiovascular disease., Arch Intern Med, 163, 2006, 10.1001/archinte.163.17.2006 · DOI · Paper page
  16. Hayden, 2002, Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force., Ann Intern Med, 136, 161, 10.7326/0003-4819-136-2-200201150-00016 · DOI · Paper page
  17. Becker, 2008, The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 776S, 10.1378/chest.08-0685 · DOI · Paper page
  18. Robless, 2001, Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease., Br J Surg, 88, 787, 10.1046/j.0007-1323.2001.01774.x · DOI · Paper page
  19. Weisman, 2002, Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events., Arch Intern Med, 162, 2197, 10.1001/archinte.162.19.2197 · DOI · Paper page
  20. Burger, 2005, Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuationreview and meta-analysis., J Intern Med, 257, 399, 10.1111/j.1365-2796.2005.01477.x · DOI · Paper page
  21. Berger, 2009, Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials., JAMA, 301, 1909, 10.1001/jama.2009.623 · DOI · Paper page
  22. Hiatt, 2002, Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy., J Intern Med, 251, 193, 10.1046/j.1365-2796.2002.00947.x · DOI
  23. Girolami, 2000, Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis., Eur J Vasc Endovasc Surg, 19, 370, 10.1053/ejvs.1999.1034 · DOI
  24. Sobel, 2008, Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 815S, 10.1378/chest.08-0686 · DOI · Paper page
  25. Singer, 2008, Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 546S, 10.1378/chest.08-0678 · DOI · Paper page
  26. Gladding, 2008, Antiplatelet drug nonresponsiveness., Am Heart J, 155, 591, 10.1016/j.ahj.2007.12.034 · DOI
  27. Newsome, 2008, Coronary artery stents. II. Perioperative considerations and management., Anesth Analg, 107, 570, 10.1213/ane.0b013e3181731e95 · DOI
  28. Patrono, 2008, Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)., Chest, 133, 199S, 10.1378/chest.08-0672 · DOI · Paper page
  29. Benedek, 1995, Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers., J Clin Pharmacol, 35, 1181, 10.1002/j.1552-4604.1995.tb04044.x · DOI
  30. Buerke, 1995, Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses., Am Heart J, 130, 465, 10.1016/0002-8703(95)90353-4 · DOI
  31. Bochner, 1988, Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function., Eur J Clin Pharmacol, 35, 287, 10.1007/BF00558267 · DOI
  32. Roth, 1975, Acetylation of prostaglandin synthase by aspirin., Proc Natl Acad Sci USA, 72, 3073, 10.1073/pnas.72.8.3073 · DOI · Paper page
  33. Burch, 1978, Inhibition of platelet prostaglandin synthetase by oral aspirin., J Clin Invest, 61, 314, 10.1172/JCI108941 · DOI · Paper page
  34. Vane, 1995, New insights into the mode of action of anti-inflammatory drugs., Inflamm Res, 44, 1, 10.1007/BF01630479 · DOI · Paper page
  35. Patrignani, 1982, Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects., J Clin Invest, 69, 1366, 10.1172/JCI110576 · DOI · Paper page
  36. Pierucci, 1989, Improvement of renal function with selective thromboxane antagonism in lupus nephritis., N Engl J Med, 320, 421, 10.1056/NEJM198902163200703 · doi:10.1056/nejm198902163200703
  37. Serebruany, 2004, Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials., Am J Hematol, 75, 40, 10.1002/ajh.10451 · DOI · Paper page
  38. Derry, 2000, Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis., BMJ, 321, 1183, 10.1136/bmj.321.7270.1183 · DOI · Paper page
  39. Lai, 2002, Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use., N Engl J Med, 346, 2033, 10.1056/NEJMoa012877 · DOI · Paper page
  40. Capone, 2005, Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects., J Am Coll Cardiol, 45, 1295, 10.1016/j.jacc.2005.01.045 · DOI · Paper page
  41. MacDonald, 2003, Effect of ibuprofen on cardioprotective effect of aspirin., Lancet, 361, 573, 10.1016/S0140-6736(03)12509-3 · DOI · Paper page
  42. Kurth, 2003, Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs., Circulation, 108, 1191, 10.1161/01.CIR.0000087593.07533.9B · DOI · Paper page
  43. Gladding, 2008, The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers., Am J Cardiol, 101, 1060, 10.1016/j.amjcard.2007.11.054 · DOI · Paper page
  44. Kimmel, 2002, Parenteral ketorolac and risk of myocardial infarction., Pharmacoepidemiol Drug Saf, 11, 113, 10.1002/pds.670 · DOI
  45. Kearney, 2006, Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis Meta-analysis of randomised trials., BMJ, 332, 1302, 10.1136/bmj.332.7553.1302 · DOI · Paper page
  46. Antman, 2007, Use of nonsteroidal antiinflammatory drugs: an update for cliniciansa scientific statement from the American Heart Association., Circulation, 115, 1634, 10.1161/CIRCULATIONAHA.106.181424 · DOI · Paper page
  47. Graham, 2005, Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study., Lancet, 365, 475, 10.1016/S0140-6736(05)17864-7 · DOI · Paper page
  48. Nussmeier, 2005, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery., N Engl J Med, 352, 1081, 10.1056/NEJMoa050330 · DOI · Paper page
  49. Angiolillo, 2009, Variability in responsiveness to oral antiplatelet therapy., Am J Cardiol, 103, 27A, 10.1016/j.amjcard.2008.11.020 · DOI
  50. Cattaneo, 2007, Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection., J Thromb Haemost, 5, 230, 10.1111/j.1538-7836.2007.02498.x · DOI · Paper page
  51. Hovens, 2007, Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review., Am Heart J, 153, 175, 10.1016/j.ahj.2006.10.040 · DOI · Paper page
  52. Krasopoulos, 2008, Aspirin resistance and risk of cardiovascular morbidity: systematic review and meta-analysis., BMJ, 336, 195, 10.1136/bmj.39430.529549.BE · DOI · Paper page
  53. Schwartz, 2005, Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction., Am J Cardiol, 95, 973, 10.1016/j.amjcard.2004.12.038 · DOI · Paper page
  54. Serebruany, 2006, Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial., Int J Clin Pract, 60, 863, 10.1111/j.1742-1241.2006.00999.x · DOI
  55. Eikelboom, 2008, Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk., Circulation, 118, 1705, 10.1161/CIRCULATIONAHA.108.768283 · DOI · Paper page
  56. Bonello, 2008, Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study., J Am Coll Cardiol, 51, 1404, 10.1016/j.jacc.2007.12.044 · DOI · Paper page
  57. Cipollone, 2000, Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina., Circulation, 102, 1007, 10.1161/01.CIR.102.9.1007 · DOI · Paper page
  58. Marcucci, 2006, Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events., Am J Cardiol, 98, 1156, 10.1016/j.amjcard.2006.05.041 · doi:10.1016/j.amjcard.2006.05.041
  59. DiChiara, 2007, The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study., Diabetes, 56, 3014, 10.2337/db07-0707 · DOI · Paper page
  60. Hall, 1997, Light versus heavy sedation after cardiac surgery: myocardial ischemia and the stress response. Maritime Heart Centre and Dalhousie University., Anesth Analg, 85, 971, 10.1213/00000539-199711000-00004 · doi:10.1213/00000539-199711000-00004
  61. Fabre, 2010, Limitations of current therapies to prevent thrombosis: a need for novel strategies., Mol Biosyst, 6, 305, 10.1039/B914375K · DOI
  62. Gurbel, 2009, The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting., Platelets, 20, 97, 10.1080/09537100802687666 · DOI
  63. van der Poll, 1990, Activation of coagulation after administration of tumor necrosis factor to normal subjects., N Engl J Med, 322, 1622, 10.1056/NEJM199006073222302 · DOI · Paper page
  64. Aird, 2001, Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis., Crit Care Med, 29, S28, 10.1097/00003246-200107001-00013 · DOI · Paper page
  65. Steinhubl, 2007, Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease., Vasc Med, 12, 113, 10.1177/1358863X07077462 · DOI
  66. Rough, 2009, Beta2 adrenoreceptor blockade attenuates the hyperinflammatory response induced by traumatic injury., Surgery, 145, 235, 10.1016/j.surg.2008.09.013 · DOI
  67. Flierl, 2009, Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response., PLoS One, 4, e4414, 10.1371/journal.pone.0004414 · DOI · Paper page
  68. Anfossi, 1996, Role of catecholamines in platelet function: pathophysiological and clinical significance., Eur J Clin Invest, 26, 353, 10.1046/j.1365-2362.1996.150293.x · DOI · Paper page
  69. Beres, 2008, Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy., Thromb Haemost, 100, 829, 10.1160/TH08-03-0158 · DOI
  70. Larsson, 1994, Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin., Circulation, 89, 1951, 10.1161/01.CIR.89.5.1951 · DOI · Paper page
  71. Golanski, 2001, Platelet hyperreactivity after coronary artery bypass grafting: the possible relevance to glycoprotein polymorphismsa preliminary report., Platelets, 12, 241
  72. Feher, 2009, The genetics of antiplatelet drug resistance., Clin Genet, 75, 1, 10.1111/j.1399-0004.2008.01105.x · DOI
  73. Hu, 2006, Chronic beta-adrenergic receptor stimulation induces cardiac apoptosis and aggravates myocardial ischemiareperfusion injury by provoking inducible nitric-oxide synthase-mediated nitrative stress., J Pharmacol Exp Ther, 318, 469, 10.1124/jpet.106.102160 · DOI
  74. Golanski, 2005, Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy., Ther Drug Monit, 27, 484, 10.1097/01.ftd.0000158084.84071.41 · DOI
  75. Mardikar, 2008, Variability in platelet response to a single daily dose of 150 mg enteric coated aspirin in a high risk population., J Assoc Physicians India, 56, 321
  76. Lordkipanidze, 2006, Aspirin resistance: truth or dare., Pharmacol Ther, 112, 733, 10.1016/j.pharmthera.2006.05.011 · DOI
  77. Hankey, 2006, Aspirin resistance., Lancet, 367, 606, 10.1016/S0140-6736(06)68040-9 · DOI · Paper page
  78. Abaci, 2005, Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes., Thromb Res, 116, 465, 10.1016/j.thromres.2005.02.005 · DOI
  79. Cornelissen, 2006, Biological efficacy of low against medium dose aspirin regimen after coronary surgery: analysis of platelet function., Thromb Haemost, 95, 476, 10.1160/TH05-10-0649 · doi:10.1160/th05-10-0649
  80. Lim, 2003, Indirect comparison meta-analysis of aspirin therapy after coronary surgery., BMJ, 327, 1309, 10.1136/bmj.327.7427.1309 · DOI
  81. Duzenli, 2008, Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin., Am J Cardiol, 102, 396, 10.1016/j.amjcard.2008.03.074 · DOI · Paper page
  82. Lev, 2006, Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance., J Am Coll Cardiol, 47, 27, 10.1016/j.jacc.2005.08.058 · DOI · Paper page
  83. Sanderson, 2005, Narrative review: aspirin resistance and its clinical implications., Ann Intern Med, 142, 370, 10.7326/0003-4819-142-5-200503010-00012 · DOI · Paper page
  84. Pamukcu, 2007, A review of aspirin resistance: definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes., J Thromb Thrombolysis, 23, 213, 10.1007/s11239-006-9043-2 · DOI
  85. Macchi, 2006, Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance., Curr Pharm Des, 12, 251, 10.2174/138161206775193064 · DOI
  86. Michelson, 2005, Aspirin resistance: position paper of the Working Group on Aspirin Resistance., J Thromb Haemost, 3, 1309, 10.1111/j.1538-7836.2005.01351.x · DOI · Paper page
  87. Frelinger, 2006, Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance., Circulation, 113, 2888, 10.1161/CIRCULATIONAHA.105.596627 · DOI · Paper page
  88. Wang, 2006, Aspirin and clopidogrel resistance: an emerging clinical entity., Eur Heart J, 27, 647, 10.1093/eurheartj/ehi684 · DOI · Paper page
  89. Serebruany, 2008, Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients., Fundam Clin Pharmacol, 22, 315, 10.1111/j.1472-8206.2008.00582.x · doi:10.1111/j.1472-8206.2008.00582.x
  90. Adams, 2008, Update to the AHAASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack., Stroke, 39, 1647, 10.1161/STROKEAHA.107.189063 · DOI · Paper page
  91. Taubert, 2004, Pharmacokinetics of clopidogrel after administration of a high loading dose., Thromb Haemost, 92, 311, 10.1160/TH04-02-0105 · DOI · Paper page
  92. Lins, 1999, Pharmacokinetic profile of 14C-labeled clopidogrel., Semin Thromb Hemost, 25, 29
  93. Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects., Blood, 108, 2244, 10.1182/blood-2006-04-013052 · DOI · Paper page
  94. Farid, 2007, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently., Clin Pharmacol Ther, 81, 735, 10.1038/sj.clpt.6100139 · DOI · Paper page
  95. Serebruany, 2005, Variability in platelet responsiveness to clopidogrel among 544 individuals., J Am Coll Cardiol, 45, 246, 10.1016/j.jacc.2004.09.067 · DOI · Paper page
  96. Shuldiner, 2009, Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy., JAMA, 302, 849, 10.1001/jama.2009.1232 · DOI · Paper page
  97. Mega, 2009, Cytochrome p-450 polymorphisms and response to clopidogrel., N Engl J Med, 360, 354, 10.1056/NEJMoa0809171 · DOI · Paper page
  98. Bonello-Palot, 2009, Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention., Am J Cardiol, 104, 1511, 10.1016/j.amjcard.2009.07.015 · doi:10.1016/j.amjcard.2009.07.015
  99. von Beckerath, 2005, Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial., Circulation, 112, 2946, 10.1161/CIRCULATIONAHA.105.559088 · DOI · Paper page
  100. Deray, 1998, Clopidogrel activities in patients with renal impairment., Clin Drug Invest, 16, 319, 10.2165/00044011-199816040-00006 · DOI
  101. Slugg, 2000, Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel., J Clin Pharmacol, 40, 396, 10.1177/00912700022008973 · doi:10.1177/00912700022008973
  102. Hochholzer, 2005, Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention., Circulation, 111, 2560, 10.1161/01.CIR.0000160869.75810.98 · DOI
  103. Taubert, 2006, Impact of P-glycoprotein on clopidogrel absorption., Clin Pharmacol Ther, 80, 486, 10.1016/j.clpt.2006.07.007 · DOI
  104. Ding, 2003, Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270., Blood, 101, 3908, 10.1182/blood-2002-10-3027 · DOI · Paper page
  105. Suh, 2006, Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel., CMAJ, 174, 1715, 10.1503/cmaj.060664 · DOI · Paper page
  106. Ho, 2008, Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome., JAMA, 299, 532, 10.1001/jama.299.5.532 · DOI · Paper page
  107. Sibbing, 2010, A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment., J Am Coll Cardiol, 55, 558, 10.1016/j.jacc.2009.09.038 · doi:10.1016/j.jacc.2009.09.038
  108. Berger, 2008, Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis., J Am Coll Cardiol, 52, 1693, 10.1016/j.jacc.2008.08.031 · DOI · Paper page
  109. Chen, 2004, Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting., J Thorac Cardiovasc Surg, 128, 425, 10.1016/j.jtcvs.2004.02.019 · DOI · Paper page
  110. Chan, 2007, Clopidogrel is safe early after on- and off-pump coronary artery bypass surgery., J Card Surg, 22, 493, 10.1111/j.1540-8191.2007.00475.x · doi:10.1111/j.1540-8191.2007.00475.x
  111. Harker, 1999, Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events., Drug Saf, 21, 325, 10.2165/00002018-199921040-00007 · DOI
  112. Bennett, 2000, Thrombotic thrombocytopenic purpura associated with clopidogrel., N Engl J Med, 342, 1773, 10.1056/NEJM200006153422402 · DOI · Paper page
  113. Lau, 2003, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction., Circulation, 107, 32, 10.1161/01.CIR.0000047060.60595.CC · DOI · Paper page
  114. Saw, 2007, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial., J Am Coll Cardiol, 50, 291, 10.1016/j.jacc.2007.01.097 · DOI · Paper page
  115. Lotfi, 2008, High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients: a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis., Am Heart J, 155, 954, 10.1016/j.ahj.2007.12.009 · DOI
  116. Trenk, 2008, Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement., Thromb Haemost, 99, 174, 10.1160/TH07-08-0503 · doi:10.1160/th07-08-0503
  117. Brophy, 2006, A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention., Am Heart J, 152, 263, 10.1016/j.ahj.2005.08.023 · DOI
  118. Neubauer, 2006, Thienopyridines and statins: assessing a potential drug-drug interaction., Curr Pharm Des, 12, 1271, 10.2174/138161206776361354 · doi:10.2174/138161206776361354
  119. Gilard, 2008, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study., J Am Coll Cardiol, 51, 256, 10.1016/j.jacc.2007.06.064 · DOI · Paper page
  120. Small, 2008, Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel., J Clin Pharmacol, 48, 475, 10.1177/0091270008315310 · DOI · Paper page
  121. Ho, 2009, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome., JAMA, 301, 937, 10.1001/jama.2009.261 · DOI · Paper page
  122. Rassen, 2009, Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome., Circulation, 120, 2322, 10.1161/CIRCULATIONAHA.109.873497 · DOI · Paper page
  123. Juurlink, 2009, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel., CMAJ, 180, 713, 10.1503/cmaj.082001 · DOI · Paper page
  124. Bhatt, 2008, ACCFACGAHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents., Circulation, 118, 1894, 10.1161/CIRCULATIONAHA.108.191087 · DOI · Paper page
  125. Hirota, 2005, The efficacy of preanesthetic proton pump inhibitor treatment for patients on long-term H2 antagonist therapy., Anesth Analg, 101, 1038, 10.1213/01.ane.0000166979.99225.a0 · doi:10.1213/01.ane.0000166979.99225.a0
  126. Devlin, 2005, Proton pump inhibitor formulary considerations in the acutely ill. Part 2. Clinical efficacy, safety, and economics., Ann Pharmacother, 39, 1844, 10.1345/aph.1G176 · DOI
  127. Ivandic, 2006, Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor., Clin Chem, 52, 383, 10.1373/clinchem.2005.059535 · doi:10.1373/clinchem.2005.059535
  128. Snoep, 2007, Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis., Am Heart J, 154, 221, 10.1016/j.ahj.2007.04.014 · DOI · Paper page
  129. Matetzky, 2004, Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction., Circulation, 109, 3171, 10.1161/01.CIR.0000130846.46168.03 · DOI · Paper page
  130. Serebruany, 2007, The clopidogrel resistance trap., Am J Cardiol, 100, 1044, 10.1016/j.amjcard.2007.04.050 · DOI
  131. Jackevicius, 2008, Cardiovascular outcomes after a change in prescription policy for clopidogrel., N Engl J Med, 359, 1802, 10.1056/NEJMsa0803410 · DOI
  132. Spertus, 2006, Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry., Circulation, 113, 2803, 10.1161/CIRCULATIONAHA.106.618066 · DOI · Paper page
  133. Gurbel, 2003, Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity., Circulation, 107, 2908, 10.1161/01.CIR.0000072771.11429.83 · DOI · Paper page
  134. Michelson, 2006, Resistance to antiplatelet drugs., Eur Heart J, 8, G53, 10.1093/eurheartj/sul056 · doi:10.1093/eurheartj/sul056
  135. Tassies, 2006, Pharmacogenetics of antithrombotic drugs., Curr Pharm Des, 12, 2425, 10.2174/138161206777698963 · doi:10.2174/138161206777698963
  136. Siller-Matula, 2007, Thienopyridines in cardiovascular disease: focus on clopidogrel resistance., Thromb Haemost, 97, 385, 10.1160/TH06-08-0420 · doi:10.1160/th06-08-0420
  137. Gori, 2008, Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents., J Am Coll Cardiol, 52, 734, 10.1016/j.jacc.2008.05.032 · doi:10.1016/j.jacc.2008.05.032
  138. Gurbel, 2005, The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting., J Am Coll Cardiol, 45, 1392, 10.1016/j.jacc.2005.01.030 · DOI · Paper page
  139. Fontana, 2008, Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C192 allele on clopidogrel responsiveness., Thromb Res, 121, 463, 10.1016/j.thromres.2007.06.012 · doi:10.1016/j.thromres.2007.06.012
  140. Abuzahra, 2008, Comparison of higher clopidogrel loading and maintenance dose to standard dose on platelet function and outcomes after percutaneous coronary intervention using drug-eluting stents., Am J Cardiol, 102, 401, 10.1016/j.amjcard.2008.03.073 · doi:10.1016/j.amjcard.2008.03.073
  141. Perneby, 2007, Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease., Thromb Haemost, 98, 1316, 10.1160/TH07-05-0323 · doi:10.1160/th07-05-0323
  142. Lim, 2004, Clopidogrel did not inhibit platelet function early after coronary bypass surgery: a prospective randomized trial., J Thorac Cardiovasc Surg, 128, 432, 10.1016/j.jtcvs.2004.03.007 · DOI
  143. Erlinge, 2008, Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo., J Am Coll Cardiol, 52, 1968, 10.1016/j.jacc.2008.07.068 · DOI · Paper page
  144. Marcucci, 2007, Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy., Thromb Haemost, 98, 844, 10.1160/TH06-11-0618 · DOI
  145. David, 1999, Antiplatelet activity of clopidogrel in coronary artery bypass graft surgery patients., Thromb Haemost, 82, 1417, 10.1055/s-0037-1614847 · DOI
  146. Angiolillo, 2009, Advances in antiplatelet therapy: agents in clinical development., Am J Cardiol, 103, 40A, 10.1016/j.amjcard.2008.11.023 · DOI
  147. Niitsu, 2005, Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity., Semin Thromb Hemost, 31, 184, 10.1055/s-2005-869524 · DOI · Paper page
  148. Jakubowski, 2007, Prasugrel: a novel thienopyridine antiplatelet agenta review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile., Cardiovasc Drug Rev, 25, 357, 10.1111/j.1527-3466.2007.00027.x · DOI · Paper page
  149. Wiviott, 2005, Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial., Circulation, 111, 3366, 10.1161/CIRCULATIONAHA.104.502815 · DOI · Paper page
  150. Wiviott, 2007, Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial., Circulation, 116, 2923, 10.1161/CIRCULATIONAHA.107.740324 · DOI · Paper page
  151. Wiviott, 2008, Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial., Lancet, 371, 1353, 10.1016/S0140-6736(08)60422-5 · DOI · Paper page
  152. Montalescot, 2009, Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial., Lancet, 373, 723, 10.1016/S0140-6736(09)60441-4 · DOI · Paper page
  153. Murphy, 2008, Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial., Eur Heart J, 29, 2473, 10.1093/eurheartj/ehn362 · DOI
  154. Sugidachi, 2000, The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties., Br J Pharmacol, 129, 1439, 10.1038/sj.bjp.0703237 · DOI · Paper page
  155. Rehmel, 2006, Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450., Drug Metab Dispos, 34, 600, 10.1124/dmd.105.007989 · DOI · Paper page
  156. Wallentin, 2008, Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease., Eur Heart J, 29, 21, 10.1093/eurheartj/ehm545 · DOI · Paper page
  157. Brandt, 2007, Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel., J Thromb Haemost, 5, 2429, 10.1111/j.1538-7836.2007.02775.x · DOI · Paper page
  158. Farid, 2007, The disposition of prasugrel, a novel thienopyridine, in humans., Drug Metab Dispos, 35, 1096, 10.1124/dmd.106.014522 · doi:10.1124/dmd.106.014522
  159. Weerakkody, 2007, Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status., Am J Cardiol, 100, 331, 10.1016/j.amjcard.2007.02.103 · doi:10.1016/j.amjcard.2007.02.103
  160. Jakubowski, 2006, The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects., J Cardiovasc Pharmacol, 47, 377, 10.1097/01.fjc.0000210069.47205.c0 · DOI
  161. Jakubowski, 2007, A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans., Br J Clin Pharmacol, 63, 421, 10.1111/j.1365-2125.2006.02792.x · DOI
  162. Braun, 2008, Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease., Thromb Haemost, 100, 626, 10.1160/TH08-05-0313 · DOI
  163. Jernberg, 2006, Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease., Eur Heart J, 27, 1166, 10.1093/eurheartj/ehi877 · DOI · Paper page
  164. Weerakkody, 2007, Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis., J Cardiovasc Pharmacol Ther, 12, 205, 10.1177/1074248407304731 · doi:10.1177/1074248407304731
  165. Payne, 2008, Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects., Platelets, 19, 275, 10.1080/09537100801891640 · doi:10.1080/09537100801891640
  166. Serebruany, 2006, Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study., Postgrad Med J, 82, 404, 10.1136/pgmj.2006.047696 · doi:10.1136/pgmj.2006.047696
  167. Bhatt, 2007, Intensifying platelet inhibition: navigating between Scylla and Charybdis., N Engl J Med, 357, 2078, 10.1056/NEJMe0706859 · DOI · Paper page
  168. Antman, 2008, Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis., J Am Coll Cardiol, 51, 2028, 10.1016/j.jacc.2008.04.002 · DOI · Paper page
  169. Farid, 2008, Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects., Pharmacotherapy, 28, 1483, 10.1592/phco.28.12.1483 · DOI
  170. Oestreich, 2010, Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events., Curr Opin Investig Drugs, 11, 340
  171. Michelson, 2009, New P2Y12 antagonists., Curr Opin Hematol, 16, 371, 10.1097/MOH.0b013e32832ea2f2 · doi:10.1097/moh.0b013e32832ea2f2
  172. Gurbel, 2010, The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C192 genotype: first experience in patients., J Thromb Haemost, 8, 43, 10.1111/j.1538-7836.2009.03648.x · DOI
  173. Cattaneo, 2007, Platelet P2 receptors: old and new targets for antithrombotic drugs., Expert Rev Cardiovasc Ther, 5, 45, 10.1586/14779072.5.1.45 · DOI
  174. Storey, 2001, Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes., Thromb Haemost, 85, 401, 10.1055/s-0037-1615596 · DOI · Paper page
  175. Jacobsson, 2002, Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction., Clin Ther, 24, 752, 10.1016/S0149-2918(02)85149-9 · DOI
  176. Greenbaum, 2007, Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial., Am Heart J, 154, 702, 10.1016/j.ahj.2007.06.001 · DOI
  177. Bhatt, 2009, Intravenous platelet blockade with cangrelor during PCI., N Engl J Med, 361, 2330, 10.1056/NEJMoa0908629 · DOI · Paper page
  178. Harrington, 2009, Platelet inhibition with cangrelor in patients undergoing PCI., N Engl J Med, 361, 2318, 10.1056/NEJMoa0908628 · DOI · Paper page
  179. Fugate, 2006, Cangrelor for treatment of coronary thrombosis., Ann Pharmacother, 40, 925, 10.1345/aph.1G120 · doi:10.1345/aph.1g120
  180. Ingall, 1999, Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy., J Med Chem, 42, 213, 10.1021/jm981072s · DOI · Paper page
  181. Storey, 2002, Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease., Platelets, 13, 407, 10.1080/0953710021000024402 · DOI
  182. Greenbaum, 2006, Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial., Am Heart J, 151, 689, 10.1016/j.ahj.2005.11.014 · DOI · Paper page
  183. Serebruany, 2007, Dyspnoea after antiplatelet agents: the AZD6140 controversy., Int J Clin Pract, 61, 529, 10.1111/j.1742-1241.2007.01294.x · DOI
  184. Cannon, 2007, Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial., J Am Coll Cardiol, 50, 1844, 10.1016/j.jacc.2007.07.053 · DOI · Paper page
  185. Cannon, 2010, Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study., Lancet, 375, 283, 10.1016/S0140-6736(09)62191-7 · DOI · Paper page
  186. Gurbel, 2010, Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study., Circulation, 121, 1188, 10.1161/CIRCULATIONAHA.109.919456 · DOI · Paper page
  187. Husted, 2006, Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin., Eur Heart J, 27, 1038, 10.1093/eurheartj/ehi754 · DOI · Paper page
  188. Teng, 2010, Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects., Eur J Clin Pharmacol, 66, 487, 10.1007/s00228-009-0778-5 · DOI · Paper page
  189. van Giezen, 2009, Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation., J Thromb Haemost, 7, 1556, 10.1111/j.1538-7836.2009.03527.x · DOI · Paper page
  190. Storey, 2009, Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3., Platelets, 20, 341, 10.1080/09537100903075324 · DOI
  191. Storey, 2007, Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes., J Am Coll Cardiol, 50, 1852, 10.1016/j.jacc.2007.07.058 · DOI · Paper page
  192. Husted, 2010, Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel., Clin Cardiol, 33, 206, 10.1002/clc.20732 · DOI
  193. Storey, 2010, Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSETOFFSET study., J Am Coll Cardiol, 56, 185, 10.1016/j.jacc.2010.01.062 · DOI · Paper page
  194. Gamboa, 2005, Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole., Stroke, 36, 2170, 10.1161/01.STR.0000179044.37760.9d · DOI
  195. De Schryver, 2007, Dipyridamole for preventing stroke and other vascular events in patients with vascular disease., Cochrane Database Syst Rev, 3, CD001820
  196. Lehmann, 1984, Persantine bioavailability problems., Clin Pharm, 3, 14
  197. FitzGerald, 1987, Dipyridamole., N Engl J Med, 316, 1247, 10.1056/NEJM198705143162005 · DOI · Paper page
  198. Derendorf, 2005, Dipyridamole bioavailability in subjects with reduced gastric acidity., J Clin Pharmacol, 45, 845, 10.1177/0091270005276738 · DOI
  199. Diener, 1996, European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke., J Neurol Sci, 143, 1, 10.1016/S0022-510X(96)00308-5 · DOI · Paper page
  200. Mahony, 1982, Dipyridamol kinetics., Clin Pharmacol Ther, 31, 330, 10.1038/clpt.1982.42 · doi:10.1038/clpt.1982.42

200 of 283 shown

Cited by

See all 203

Metadata

Authors
Hall, R., & Mazer, C. D.
Venue
Anesthesia & Analgesia
Published
2011-02
Volume
112
Issue
2
Pages
292-318
ISSN
0003-2999 (ISSN-L)
OpenAlex
W2049222615
Cited by
203
References
11
FWCI
12.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. https://app.cochat.ai/papers/10.1213/ane.0b013e318203f38d
The paper
Hall, R., & Mazer, C. D. (2011). Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0b013e318203f38d

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.